Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

sections

Central nervous system agents

Promising early results for lisdexamfetamine as treatment for symptoms of menopause

Menopausal women frequently report cognitive deficits. A new therapy to address these deficits may be on the horizon, with promising early results for the psychostimulant lisdexamfetamine, which is used to treat attention deficit-hyperactivity disorder

Source: Dreamstime.com

Lisdexamfetamine had positive effects on cognitive function in menopausal women but also increased systolic blood pressure and heart rate

Menopausal women frequently report cognitive deficits, particularly in higher-level skills used to control other cognitive behaviours — collectively known as executive functions (EF). A new therapy to address these deficits may be on the horizon, with promising early results for the psychostimulant lisdexamfetamine, which is already used to treat attention deficit-hyperactivity disorder.

In a small trial involving 32 healthy perimenopausal and postmenopausal women with new-onset EF complaints, lisdexamfetamine was significantly more effective than placebo for improving scores on the Brown Attention Deficit Disorder Scale and for improving delayed paragraph recall. A potential drawback was the drug’s effect on systolic blood pressure and heart rate, both of which were increased significantly by lisdexamfetamine.

Long-term studies are warranted to explore the risk-benefit profile of the drug in menopausal women, say the researchers in Psychopharmacology[1] (online, 11 June 2015). 

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20068817

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.